HF10 is a type of spinal cord stimulation therapy that uses high-frequency electrical pulses (10,000 Hz) to treat chronic pain without causing the tingling sensations associated with older stimulators. Developed by Nevro and delivered through its Senza device system, HF10 received FDA approval in 2015 for chronic back and leg pain and has since been cleared for painful diabetic neuropathy. It represents a significant shift from traditional spinal cord stimulation, which operates at roughly 40 to 50 Hz and relies on replacing pain with a buzzing or tingling feeling called paresthesia.
How HF10 Differs From Traditional Stimulation
Traditional spinal cord stimulators work by sending low-frequency electrical pulses into the spinal cord to create a tingling sensation that masks pain. The goal is to overlap that tingling with the area where you feel pain, essentially trading one sensation for another. This approach requires precise lead placement while the patient is awake, so the surgeon can confirm the tingling covers the right spot.
HF10 takes a fundamentally different approach. It delivers 10,000 pulses per second (compared to about 40 for traditional devices), but each pulse is much shorter and uses less power. The pulse width is 30 microseconds versus 400 for conventional stimulators, and the typical current for back pain is 1 to 5 milliamps compared to 4 to 6. This combination provides pain relief without producing any tingling at all. Because there’s no paresthesia to map, lead placement is based on spinal anatomy alone, and patients can stay sedated throughout the procedure rather than being woken up to confirm sensation coverage.
Why Paresthesia-Free Matters
The absence of tingling isn’t just a comfort preference. With traditional stimulators, patients often experience uncomfortable surges of stimulation during movement or everyday activities, like bending, coughing, or rolling over in bed. These surges can be jarring enough that some people reduce how often they use their device, undermining its effectiveness. Research from the 24-month SENZA trial noted that paresthesia-related discomfort directly influences long-term compliance with traditional stimulation. Because HF10 produces no paresthesia, those issues don’t arise, which helps explain why patients tend to use the therapy more consistently over time.
What the Clinical Evidence Shows
The landmark study for HF10 is the SENZA randomized controlled trial, which compared it head-to-head against traditional spinal cord stimulation. At three months, 84.5% of HF10 patients achieved at least 50% reduction in back pain, and 83.1% hit that threshold for leg pain. These response rates held up at the 24-month follow-up, establishing HF10 as superior to traditional low-frequency stimulation for chronic back and leg pain.
More recently, a randomized clinical trial tested HF10 for painful diabetic neuropathy, a condition that causes burning, shooting pain in the feet and legs and is notoriously difficult to treat with medications alone. The results were striking: 79% of patients receiving HF10 plus standard medical care achieved at least 50% pain relief at six months, compared to just 5% of those on medical care alone. Average pain scores dropped from 7.6 out of 10 to 1.7 in the stimulation group, while the medication-only group saw essentially no change. Perhaps most surprising, 62% of HF10 patients showed measurable improvements on neurological exams, suggesting the therapy may do more than mask pain.
FDA-Approved Uses
The Senza system is currently FDA-approved for two categories of chronic pain. The first covers chronic intractable pain of the trunk or limbs, specifically failed back surgery syndrome, intractable low back pain, and leg pain. The second, added later, covers chronic pain in the lower limbs caused by diabetic neuropathy, but only when the device is programmed to deliver the 10 kHz frequency.
The Trial Period Before Implant
Before committing to a permanent device, you go through a trial phase that typically lasts about a week. During a 30- to 90-minute outpatient procedure, thin flexible wires are inserted near your spine using a specialized needle. These leads connect to an external stimulator that’s secured to your back, letting you test the therapy during normal daily activities. If the trial delivers meaningful pain relief, you and your doctor can proceed with a permanent implant. If not, the leads are simply removed.
Living With the Device
The implanted pulse generator sits under the skin, typically near the hip or buttock. Rechargeable spinal cord stimulators generally last around 9 years before needing replacement, based on real-world data from the Medicare population. The tradeoff is recharging: because HF10 operates at high frequency, it draws more power than traditional devices, and some patients need to charge daily, with sessions that can last several hours depending on their stimulation settings. The recharging process uses an external pad held against the skin over the implant.
Risks and Complications
Spinal cord stimulation, including HF10, carries real risks. An analysis of adverse events reported to Australia’s medical device regulator found that device malfunction was the most common problem, accounting for more than half of all reported events. Lead migration or fracture made up about 35% of device-related issues, meaning the thin wires can shift from their original position or break over time. Other reported complications included pain at the implant site, infection or inflammatory reactions, and, less commonly, headaches from spinal fluid leaks during the procedure.
Roughly 4 out of every 10 implanted devices in the dataset were eventually removed, and 80% of adverse events required some form of surgical intervention. These numbers cover all spinal cord stimulators and not HF10 specifically, but they reflect the general reality of implanted neurostimulation devices. Most complications are manageable, but revision surgery to reposition leads or replace components is not uncommon over the life of the device.